Logo image of PRME

PRIME MEDICINE INC (PRME) Stock Fundamental Analysis

USA - NASDAQ:PRME - US74168J1016 - Common Stock

5.68 USD
-0.55 (-8.83%)
Last: 10/10/2025, 8:52:14 PM
5.7 USD
+0.02 (+0.35%)
After Hours: 10/10/2025, 8:52:14 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to PRME. PRME was compared to 536 industry peers in the Biotechnology industry. While PRME seems to be doing ok healthwise, there are quite some concerns on its profitability. PRME is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PRME has reported negative net income.
PRME had a negative operating cash flow in the past year.
In the past 5 years PRME always reported negative net income.
PRME had a negative operating cash flow in each of the past 5 years.
PRME Yearly Net Income VS EBIT VS OCF VS FCFPRME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

The Return On Assets of PRME (-71.42%) is worse than 62.50% of its industry peers.
PRME has a Return On Equity of -327.43%. This is in the lower half of the industry: PRME underperforms 72.57% of its industry peers.
Industry RankSector Rank
ROA -71.42%
ROE -327.43%
ROIC N/A
ROA(3y)-69.15%
ROA(5y)-55.54%
ROE(3y)-107.23%
ROE(5y)-82.73%
ROIC(3y)N/A
ROIC(5y)N/A
PRME Yearly ROA, ROE, ROICPRME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

PRME does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRME Yearly Profit, Operating, Gross MarginsPRME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

6

2. Health

2.1 Basic Checks

PRME does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PRME has been increased compared to 1 year ago.
The number of shares outstanding for PRME has been increased compared to 5 years ago.
There is no outstanding debt for PRME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PRME Yearly Shares OutstandingPRME Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
PRME Yearly Total Debt VS Total AssetsPRME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

PRME has an Altman-Z score of -3.00. This is a bad value and indicates that PRME is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -3.00, PRME perfoms like the industry average, outperforming 45.71% of the companies in the same industry.
PRME has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3
ROIC/WACCN/A
WACC9.47%
PRME Yearly LT Debt VS Equity VS FCFPRME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 3.56 indicates that PRME has no problem at all paying its short term obligations.
The Current ratio of PRME (3.56) is comparable to the rest of the industry.
PRME has a Quick Ratio of 3.56. This indicates that PRME is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.56, PRME is in line with its industry, outperforming 43.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.56
Quick Ratio 3.56
PRME Yearly Current Assets VS Current LiabilitesPRME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

PRME shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.11%, which is quite impressive.
PRME shows a strong growth in Revenue. In the last year, the Revenue has grown by 739.42%.
EPS 1Y (TTM)28.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.87%
Revenue 1Y (TTM)739.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PRME is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.03% yearly.
Based on estimates for the next years, PRME will show a very strong growth in Revenue. The Revenue will grow by 44.53% on average per year.
EPS Next Y26.14%
EPS Next 2Y19.56%
EPS Next 3Y13.3%
EPS Next 5Y9.03%
Revenue Next Year780.04%
Revenue Next 2Y77.83%
Revenue Next 3Y176.76%
Revenue Next 5Y44.53%

3.3 Evolution

PRME Yearly Revenue VS EstimatesPRME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
PRME Yearly EPS VS EstimatesPRME Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRME. In the last year negative earnings were reported.
Also next year PRME is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRME Price Earnings VS Forward Price EarningsPRME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRME Per share dataPRME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PRME's earnings are expected to grow with 13.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.56%
EPS Next 3Y13.3%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PRME!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRIME MEDICINE INC

NASDAQ:PRME (10/10/2025, 8:52:14 PM)

After market: 5.7 +0.02 (+0.35%)

5.68

-0.55 (-8.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)10-31 2025-10-31
Inst Owners44.27%
Inst Owner Change0%
Ins Owners11.72%
Ins Owner Change1.37%
Market Cap993.20M
Analysts80
Price Target6.97 (22.71%)
Short Float %13.38%
Short Ratio5.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.53%
Min EPS beat(2)-22.51%
Max EPS beat(2)-10.55%
EPS beat(4)1
Avg EPS beat(4)-4.94%
Min EPS beat(4)-22.51%
Max EPS beat(4)22.47%
EPS beat(8)2
Avg EPS beat(8)-9.8%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.38%
Min Revenue beat(2)-27.12%
Max Revenue beat(2)35.89%
Revenue beat(4)2
Avg Revenue beat(4)138.95%
Min Revenue beat(4)-97.38%
Max Revenue beat(4)644.42%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-7.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.67%
EPS NY rev (1m)0%
EPS NY rev (3m)7.83%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.64%
Revenue NY rev (1m)0%
Revenue NY rev (3m)36.97%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 200.2
P/FCF N/A
P/OCF N/A
P/B 16.32
P/tB 16.32
EV/EBITDA N/A
EPS(TTM)-1.56
EYN/A
EPS(NY)-0.94
Fwd EYN/A
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS0.03
BVpS0.35
TBVpS0.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -71.42%
ROE -327.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.15%
ROA(5y)-55.54%
ROE(3y)-107.23%
ROE(5y)-82.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 103.26%
Cap/Sales 142.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.56
Quick Ratio 3.56
Altman-Z -3
F-Score5
WACC9.47%
ROIC/WACCN/A
Cap/Depr(3y)343.92%
Cap/Depr(5y)671.96%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.87%
EPS Next Y26.14%
EPS Next 2Y19.56%
EPS Next 3Y13.3%
EPS Next 5Y9.03%
Revenue 1Y (TTM)739.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year780.04%
Revenue Next 2Y77.83%
Revenue Next 3Y176.76%
Revenue Next 5Y44.53%
EBIT growth 1Y8.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.21%
EBIT Next 3Y7.66%
EBIT Next 5YN/A
FCF growth 1Y31.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.21%
OCF growth 3YN/A
OCF growth 5YN/A